AR
TPTX

Advisory Research’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Advisory Research’s Portfolio TPTX Stock Details TPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-7,248
Closed -$686K – 422
2021
Q1 		$686K Sell
7,248
-1,418
-16% -$169K 0.05% 240
2020
Q4 		$1.06M Sell
8,666
-2,173
-20% -$238K 0.08% 187
2020
Q3 		$947K Sell
10,839
-6,308
-37% -$439K 0.09% 184
2020
Q2 		$1.11M Buy
17,147
+3,853
+29% +$222K 0.1% 164
2020
Q1 		$594K Sell
13,294
-6,477
-33% -$344K 0.04% 172
2019
Q4 		$1.23M Buy
19,771
+9,273
+88% +$441K 0.06% 161
2019
Q3 		$395K Buy
+10,498
New +$457K 0.02% 273

Other funds holding TPTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Advisory Research's TPTX Position: Q2 2021 in Review

Advisory Research sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q2 2021, closing a stake of 7,248 shares — an estimated $686K sold.

Advisory Research first reported a position in TPTX in Q3 2019 and held it in 7 quarters. The position peaked at $1.23M in Q4 2019. 190 funds tracked by Wall St. Rank hold TPTX as of Q2 2021.

  • Advisory Research reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Advisory Research sold 7,248 Turning Point Therapeutics, Inc. Common Stock shares in Q2 2021, an estimated $686K.
  • Advisory Research first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q3 2019 and held it in 7 quarters.
  • Advisory Research's Turning Point Therapeutics, Inc. Common Stock position peaked at $1.23M in Q4 2019.
  • 190 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q2 2021.

Based on Advisory Research's 13F filing for Q2 2021, filed 16 Aug 2021.